Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : Jazz save search
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav®
Published: 2023-10-23 (Crawled : 12:00) - biospace.com/
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -1.39%
H: 0.09%
C: -2.36%
xywav treatment pharmaceuticals
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Published: 2023-09-22 (Crawled : 15:00) - biospace.com/
LGND | $68.58 -5.37% -5.67% 250K
|
Health Technology
|
| O: -0.07%
H: 1.1%
C: -0.34%
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: -0.72%
enrylaze approval treatment pharmaceuticals leukemia
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Published: 2023-09-21 (Crawled : 22:00) - prnewswire.com
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: -0.72%
enrylaze approval treatment pharmaceuticals leukemia
Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: 0.06%
H: 2.72%
C: 2.14%
jzp458 chmp positive treatment pharmaceuticals leukemia
Sleep Disorders Treatment Global Market Report 2023: Growing Demand for Home Sleep Tests Presents Opportunities
Published: 2023-03-31 (Crawled : 19:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
| Email alert
Add to watchlist
VTRS | News A | $11.235 -0.13% -0.13% 5.1M
|
Health Technology
| Email alert
Add to watchlist
report treatment global growing home market
Dravet syndrome treatment market size to increase by USD 575.14 million; North America to contribute 38% of market growth - Technavio
Published: 2023-01-17 (Crawled : 19:00) - prnewswire.com
VTRS | News A | $11.235 -0.13% -0.13% 5.1M
|
Health Technology
|
| O: -0.17%
H: 0.25%
C: -2.96%
TMO | News | $548.38 0.66% 0.29% 1.5M
|
Health Technology
|
| O: 0.56%
H: 0.97%
C: -1.87%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -0.46%
H: 0.2%
C: -1.92%
XENE | $40.0 0.3% 0.3% 390K
|
Health Technology
|
| O: -0.17%
H: 1.88%
C: -0.58%
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -0.46%
H: 1.9%
C: -0.12%
america treatment growth market dravet syndrome
Spasticity Treatment Market - 41% of Growth to Originate from North America| Evolving Opportunities with Allergan Plc & Alembic Pharmaceuticals Ltd. | Technavio
Published: 2022-04-23 (Crawled : 04:20) - prnewswire.com
ENDP | News | $0.2926 -9.6%
|
Health Technology
| Email alert
Add to watchlist
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
| Email alert
Add to watchlist
MDT | $80.57 1.37% 0.0% 5M
|
Health Technology
| Email alert
Add to watchlist
treatment growth market
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder
Published: 2021-12-30 (Crawled : 14:00) - biospace.com/
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: 0.09%
H: 0.74%
C: -2.58%
jzp150 treatment phase 2 als order trial enroll
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor
Published: 2021-12-15 (Crawled : 13:30) - biospace.com/
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -0.93%
H: 1.39%
C: 0.5%
jzp385 treatment phase 2 als phase 2b trial enroll
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
zepzelca treatment trial lung cancer cancer phase 3
Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -3.5%
H: 0.0%
C: 0.0%
treatment lung cancer cancer
FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment
Published: 2021-08-12 (Crawled : 21:00) - fda.gov
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -0.14%
H: 1.0%
C: -2.26%
treatment fda granted grant
GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex
Published: 2021-08-10 (Crawled : 09:00) - prnewswire.com
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -0.32%
H: 0.12%
C: -3.88%
treatment sclerosis approval
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Published: 2021-07-01 (Crawled : 01:00) - prnewswire.com
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: 1.71%
H: 1.13%
C: 0.28%
treatment fda fda approval leukemia approval
Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
Published: 2021-03-30 (Crawled : 23:00) - prnewswire.com
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: 0.37%
H: 0.84%
C: -1.63%
treatment fda myeloid leukemia fda approval leukemia approval acute myeloid leukemia
Global Acute Lymphoblastic Leukemia Treatment Market Research Report (2020 to 2025) - by Types of Cell, Therapy and Region
Published: 2021-03-24 (Crawled : 17:00) - prnewswire.com
TAK | News | $13.36 0.91% -0.52% 1.6M
|
Health Technology
|
| O: -0.36%
H: 0.36%
C: -0.21%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.86%
H: 1.01%
C: 0.53%
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 0.95%
H: 0.91%
C: -9.38%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.25%
H: 0.39%
C: 0.27%
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: 0.54%
H: 1.24%
C: -0.9%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.22%
H: 1.09%
C: -0.02%
GMAB | News | $28.97 0.94% 0.93% 450K
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: -2.59%
TECH | $62.79 1.08% 1.07% 830K
|
Health Technology
|
| O: 0.32%
H: 1.09%
C: -2.18%
treatment therapy leukemia research
Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Published: 2020-12-21 (Crawled : 20:11) - biospace.com/
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: -1.63%
H: 2.32%
C: 1.34%
license leukemia submission treatment
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.